ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Therapeutic Solutions International Announces Formation of ALS Biologics Inc to Commercialize Regenerative Technologies Related to Dreaded Motor Neuron Disease

Clinical Stage Stem Cell Company to Expand on Promising Patient Experiences by Launching Subsidiary Company

Therapeutic Solutions International, Inc. (TSOI), announced today the formation of ALS Biologics Inc, a subsidiary company dedicated to accelerating development of the Company’s assets related to Amyotrophic Lateral Sclerosis, a progressive motor neuron degenerative disease for which no cure exists. The company was formed based on previous positive observations in patients treated with the Company’s ALScell (JadiCell) product under the Right to Try Law.

“Stem cells do not work in isolation. By having had the opportunity to treat numerous patients with neurodegenerative conditions such as ALS in a practical setting, we have learned numerous ways to improve outcome, with practical techniques that we are packaging into this new company dedicated to providing new directions in eventually curing this terrible disease,” said Dr. James Veltmeyer, Chief Medical Officer of Therapeutic Solutions International. “Current treatments offer marginal benefit with the average survival time of patients with ALS being two to five years according to the ALS Association1. This needs to change. We plan to take our current intellectual property and findings and position them in a manner for greater clinical development and accelerated patient access.”

“Having been coinventor of the numerous intellectual properties amassed in Therapeutic Solutions International, I believe it is important to place certain indications into specific companies in order to facilitate focus and concentration of expertise,” said Thomas Ichim, Ph.D., Interim CEO of ALS Biologics and Board Member of Therapeutic Solutions International.

“I am proud to say that the team at TSOI has truly transformed itself into a medical 'Innovation Factory' of ideas, patents, and clinical protocols,” stated Timothy Dixon, President, and CEO of Therapeutic Solutions International. “We anticipate IND filing for treatment of ALS on or before the second quarter of 2024.”

About Therapeutic Solutions International, Inc.

Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is www.therapeuticsolutionsint.com.

About ALS Biologics, Inc.

ALS Biologics is a wholly owned subsidiary of Therapeutic Solutions International. The Company's corporate website is www.alsbiologics.com.

1 Helping You Understand ALS | The ALS Association

Contacts

Recent Quotes

View More
Symbol Price Change (%)
AMZN  245.06
-4.04 (-1.62%)
AAPL  273.98
-1.27 (-0.46%)
AMD  256.24
+18.72 (7.88%)
BAC  54.09
+0.46 (0.86%)
GOOG  287.22
-4.52 (-1.55%)
META  611.35
-15.73 (-2.51%)
MSFT  510.83
+2.15 (0.42%)
NVDA  192.34
-0.81 (-0.42%)
ORCL  227.28
-8.87 (-3.76%)
TSLA  431.12
-8.50 (-1.93%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.